Abstract
941 ISSN 1743-5889 10.2217/NNM.12.63 © 2012 Future Medicine Ltd Nanomedicine (2012) 7(7), 941–944 “...neuroAIDS becomes difficult to control due to poor bioavailability of the therapeutic agents in the brain and hence there is no evidence for decline in incidences of neuroAIDS globally. Therefore, there is an urgency for nanotherapeutics, which may cross the blood–brain barrier to release sufficient amounts of a drug in the brain to curb neuroAIDS.”
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
